Effect of Platelet-Rich Plasma (PRP) versus Autologous Whole Blood on Pain and Function Improvement in Tennis Elbow: A Randomized Clinical Trial

Seyed Ahmad Raeissadat, Leyla Sedighipour, Seyed Mansoor Rayegani, Mohammad Hasan Bahrami, Masume Bayat, Rosa Rahimi, Seyed Ahmad Raeissadat, Leyla Sedighipour, Seyed Mansoor Rayegani, Mohammad Hasan Bahrami, Masume Bayat, Rosa Rahimi

Abstract

Background. Autologous whole blood and platelet-rich plasma (PRP) have been both suggested to treat chronic tennis elbow. The aim of the present study was to compare the effects of PRP versus autologous whole blood local injection in chronic tennis elbow. Methods. Forty patients with tennis elbow were randomly divided into 2 groups. Group 1 was treated with a single injection of 2 mL of autologous PRP and group 2 with 2 mL of autologous blood. Tennis elbow strap, stretching, and strengthening exercises were administered for both groups during a 2-month followup. Pain and functional improvements were assessed using visual analog scale (VAS), modified Mayo Clinic performance index for the elbow, and pressure pain threshold (PPT) at 0, 4, and 8 weeks. Results. All pain and functional variables including VAS, PPT, and Mayo scores improved significantly in both groups 4 weeks after injection. No statistically significant difference was noted between groups regarding pain scores in 4-week follow-up examination (P > 0.05). At 8-week reevaluations, VAS and Mayo scores improved only in PRP group (P < 0.05). Conclusion. PRP and autologous whole blood injections are both effective to treat chronic lateral epicondylitis. PRP might be slightly superior in 8-week followup. However, further studies are suggested to get definite conclusion.

Figures

Figure 1
Figure 1
CONSORT 2010 flow diagram.
Figure 2
Figure 2
Mean of Mayo score in PRP and autologous whole blood (AWB) groups at baseline, 4 weeks, and 8 weeks after therapy.
Figure 3
Figure 3
Mean of VAS at baseline in PRP and autologous whole blood (AWB) groups at baseline, 4 weeks, and 8 weeks after therapy.
Figure 4
Figure 4
Mean of pain pressure threshold (PPT) in PRP and autologous whole blood (AWB) groups at baseline, 4 weeks, and 8 weeks after therapy.

References

    1. Childress MA, Beutler A. Management of chronic tendon injuries. American Family Physician. 2013;87:486–490.
    1. Chourasia AO, Buhr KA, Rabago DP, et al. Relationships between biomechanics, tendon pathology, and function in individuals with lateral epicondylosis. Journal of Orthopaedic & Sports Physical Therapy. 2013;43:368–378.
    1. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. American Journal of Sports Medicine. 2006;34(11):1774–1778.
    1. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. American Journal of Sports Medicine. 2010;38(2):255–262.
    1. Kazemi M, Azma K, Tavana B, Rezaiee Moghaddam F, Panahi A. Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy. American Journal of Physical Medicine and Rehabilitation. 2010;89(8):660–667.
    1. Molloy T, Wang Y, Murrell GAC. The roles of growth factors in tendon and ligament healing. Sports Medicine. 2003;33(5):381–394.
    1. Crane D, Everts P. Platelet rich plasma (PRP) matrix grafts. Practical Pain Management. 2008;8:11–26.
    1. Tate K, Crane D. Platelet rich plasma grafts in musculoskeletal medicine. The Journal of Prolotherapy. 2010;2:371–376.
    1. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Ethics in Science and Environmental Politics. 2008:1–10.
    1. Edwards SG, Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. Journal of Hand Surgery. 2003;28(2):272–278.
    1. Connell DA, Ali KE, Ahmad M, Lambert S, Corbett S, Curtis M. Ultrasound-guided autologous blood injection for tennis elbow. Skeletal Radiology. 2006;35(6):371–377.
    1. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. American Journal of Sports Medicine. 2011;39(10):2130–2134.
    1. Boonstra AM, Schiphorst Preuper HR, Reneman MF, Posthumus JB, Stewart RE. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. International Journal of Rehabilitation Research. 2008;31(2):165–169.
    1. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994;56(2):217–226.
    1. Turchin DC, Beaton DE, Richards RR. Validity of observer-based aggregate scoring systems as descriptors of elbow pain, function, and disability. Journal of Bone and Joint Surgery. American. 1998;80(2):154–162.
    1. Morrey BF, An KN. Functional evaluation of the elbow. In: Morrey BF, editor. The Elbow and Its Disorders. 3rd edition. Philadelphia, Pa, USA: WB Saunders; 2000. p. p. 82.
    1. De Boer YA, Hazes JMW, Winia PCA, Brand R, Rozing PM. Comparative responsiveness of four elbow scoring instruments in patients with rheumatoid arthritis. Journal of Rheumatology. 2001;28(12):2616–2623.
    1. Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. British Journal of Sports Medicine. 2011;45(12):966–971.
    1. Rabago D, Best TM, Zgierska AE, Zeisig E, Ryan M, Crane D. A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma. British Journal of Sports Medicine. 2009;43(7):471–481.
    1. Kaux JF, Crielaard JM. Platelet-rich plasma application in the management of chronic tendinopathies. Acta Orthopaedica Belgica. 2013;79:10–15.
    1. Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy—future or trend? Arthritis Research & Therapy. 2012;14:p. 219.
    1. Raeissadat SA, Rayegani SM, Babaee M, Ghorbani E. The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Research and Treatment. 2013;2013:7 pages.165967
    1. Kon E, Filardo G. PRP or not PRP? That is the question. Knee Surgery, Sports Traumatology, Arthroscopy. 2011;19(6):870–871.
    1. Monto RR. Platelet rich plasma treatment for chronic Achilles tendinosis. Foot & Ankle International. 2012;33:379–385.
    1. Gosens T, Den Oudsten BL, Fievez E, van ’t Spijker P, Fievez A. Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy: a prospective cohort study and the influence of previous treatments. International Orthopaedics. 2012;36(9):1941–1946.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit